Rezolute Completes Enrollment in Phase 3 Trial for Tumor…

Event summary

Rezolute has fully enrolled 16 participants in its Phase 3 upLIFT study for ersodetug in tumor hyperinsulinism.
Topline results from the study are expected mid-December 2026.
7 out of 8 initial participants met the primary endpoint, achieving at least a 50% reduction in glucose infusion rate.
Ersodetug has been well-tolerated with no drug-related safety findings reported.
The company plans to continue its expanded access program for compassionate use.

The big picture

Rezolute's completion of enrollment in the Phase 3 upLIFT study marks a critical step in developing a treatment for tumor hyperinsulinism, a rare and life-threatening condition. The study's focus on a small, targeted patient population highlights the challenges and opportunities in rare disease therapeutics. Positive results could accelerate Rezolute's path to market and solidify its position in the ultra-rare disease space.

What we're watching

Clinical Efficacy: Whether the topline results in mid-December 2026 will confirm the initial positive outcomes and meet the statistical significance criteria.
Regulatory Pathway: The pace at which Rezolute can advance both tumor and congenital hyperinsulinism indications in 2027 if the study outcomes are favorable.
Market Potential: How the success of ersodetug in tumor hyperinsulinism could position Rezolute in the broader market for refractory hypoglycemia treatments.